In summary, our study showed that high expression levels of SLC7A11 and GPX4 are associated with platinum resistance in ovarian cancer patients, and that a high co‐expression level of SLC7A11–GPX4 was a superior predictor for poor prognosis and platinum resistance in EOC compared with the corresponding individual parameters (SLC7A11 or GPX4 expression). This evidence concerns the gene GPX4 and ovarian cancer.